Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — Q1 2025 Earnings Presentation
17 slides from Wuxi Apptec Co., Ltd. Class A's earnings presentation, Apr 29, 2025
Slide 1: WuXi AppTec First Quarterly 2025 Results
WuXi AppTec First Quarterly 2025 Results April 29, 2025 1 603259.SH / 2359.HK
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Results Overview, Segment Performance, Financial Performance, Company Outlook
01 Results Overview 02 Segment Performance 03 Financial Performance 04 Company Outlook 3 Note: Unless otherwise stated, all financials disclosed in this presentation are prepared based on IFRSs. The currency is RMB. All net profit disclosed in this presentation represents net profit attributable to
Slide 4: 1. Results Overview
1. Results Overview 4
Slide 5: Q1 2025 Revenue & Profit Resumed Double Digit Growth, Revenue Up 21.0% YoY
Q1 2025 Revenue & Profit Resumed Double Digit Growth, with Revenue Up 21.0% YoY and Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY Revenue Adjusted Non-IFRS Net Profit Backlog for Continuing Operations RMB billion RMB billion RMB billion Discontinued Operat
Slide 6: Stability and Resilience of the Company's Financial Performance
Diversified Revenue Streams1 from Customers Across Regions Ensure the Stability and Resilience of the Company’s Financial Performance RMB billion China Europe 1.53Bn，-1.3% 1.30Bn，+26.2% Revenue contribution: 16% Revenue contribution: 13% US 6.38Bn，+28.4% Revenue contribution: 66% Japan, Korea & Othe
Slide 7: 2. Segment Performance
2. Segment Performance ze S| od
Slide 8: WuXi Chemistry: CRDMO Business Model Drives Continuous Growth
WuXi Chemistry: CRDMO Business Model Drives Continuous Growth, Q1 2025 Revenue Up 32.9% YoY, with TIDES Revenue Up 187.6% YoY Revenue & Gross Profit Margin CRDMO Business Model Drives Continuous Growth ⚫ WuXi Chemistry Q1 revenue up 32.9% YoY to 7.39bn ⚫ With continued optimization of production pro
Slide 9: WuXi Chemistry: Growing Small Molecule CRDMO Pipeline
WuXi Chemistry: Growing Small Molecule CRDMO Pipeline Driven by “Follow the Molecule + Win the Molecule” Strategies “R” 6%↑ 460,000+ 14,751 compounds Compounds Q1 2025 Newly Added Molecules to D&M Pipeline 2,868 Preclinical & Phase I in Total 203 Including 75 Molecules Converted from R to D 368 Phas
Slide 10: WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leading Positions
WuXi Testing1: Drug Safety Evaluation Service & SMO Maintain Leading Positions Revenue & Gross Profit Margin1 Lab Testing Services1 ⚫ Q1 revenue of lab testing services down 4.9% YoY to 0.88bn, due to market RMB billion impact as pricing gradually reflected in revenue along with backlog conversion,
Slide 11: WuXi Biology: Continues to Generate Downstream Opportunities
WuXi Biology: Continues to Generate Downstream Opportunities; In Vitro & In Vivo Business Synergies and New Modality Business Drive Growth Revenue & Gross Profit Margin RMB billion ⚫ Follow the science and continuously strengthen drug discovery Adjusted Non- capabilities in emerging areas. Efficient
Slide 12: 3. Financial Performance
3. Financial Performance 12
Slide 13: Continue to Improve Operating Efficiency, Maintaining Stable Profit Margin
Continue to Improve Operating Efficiency and Leverage Management Resilience, Maintaining Stable Profit Margin Adjusted Non-IFRS Gross Profit Adjusted Non-IFRS GPM* Adjusted Non-IFRS Net Profit Adjusted Non-IFRS NPM RMB billion RMB billion 40.3% 38.0% 38.7% 42.0% 41.6% 38.7% 41.9% 22.0% 22.4% 23.9% 2
Slide 14: Q1 2025 Operating Cash Flow Up 41.8% YoY to 3.03 Billion
With Continued Business Growth, Efficient Operations and Constant Improvement of Financial Management Capabilities, Q1 2025 Operating Cash Flow Up 41.8% YoY to 3.03 Billion RMB billion Capex1 12.64 Operating Cash Flow 11.99 9.97 10.23 6.94 5.52 4.38 3.83 4.00 3.03 3.03 Q1 2024 0.73 Q1 2024 2.14 0.81
Slide 15: 4. Company Outlook
4. Company Outlook i ls Be 3)
Slide 16: Company Outlook
Company Outlook Focus on the CRDM "O" business model, striving for highly efficient & exceptional services and lean operations ("O") • Continue to focus on our unique integrated CRDMO core business, and accelerate global D&M capacity construction • Leveraging customers’ ongoing demand for enabling s
Slide 17: Company Outlook
Company Outlook Remain committed to rewarding shareholders and upholding the Company's value • The Company’s Board of Directors has proposed the below for approval by the Annual General Meeting: - maintain 30% annual cash dividend ratio (~RMB2.8 billion) - an additional one-time special dividend of